Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Elevated expression of the EZH2 gene in CALR-mutated patients with primary myelofibrosis

Elevated expression of the EZH2 gene in CALR-mutated patients with primary myelofibrosis Primary myelofibrosis (PMF) is one of the BCR/ABL-negative myeloproliferative neoplasms (MPNs), characterized by the diffuse fibrous hyperproliferation, bone marrow osteosclerosis, extramedullary hematopoiesis, and marked splenomegaly. The patients with PMF have an insidious onset, a long duration of clinical course, and the deteriorated quality of life. It has been reported that the CALR gene 9 exon mutations were detected in 25–30% PMF patients, particularly as high as 80% in the JAK2/MPL-negative ones. As the second most common mutation in BCR/ABL-negative MPNs, CALR mutation has been included in the latest World Health Organization (WHO) classification criteria as one of the main diagnostic criteria for both essential thrombocythemia (ET) and PMF. Moreover, the CALR mutations indicated a favorable prognosis, which the mechanism is still under investigation. It was demonstrated that a characterized high expression of EZH2 and SUZ12 in CALR-mutated patients. Taking EZH2 as the research entry point, we initially discussed the mechanism that the CALR-positive patients with PMF exhibited a better prognosis in the current study. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Hematology Springer Journals

Elevated expression of the EZH2 gene in CALR-mutated patients with primary myelofibrosis

Download PDF
16 pages
Read Article

Loading next page...
 
/lp/springer_journal/elevated-expression-of-the-ezh2-gene-in-calr-mutated-patients-with-3WFbqHBmia
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Medicine & Public Health; Hematology; Oncology
ISSN
0939-5555
eISSN
1432-0584
DOI
10.1007/s00277-018-3287-8
pmid
29560522
Publisher site
See Article on Publisher Site

Abstract

Primary myelofibrosis (PMF) is one of the BCR/ABL-negative myeloproliferative neoplasms (MPNs), characterized by the diffuse fibrous hyperproliferation, bone marrow osteosclerosis, extramedullary hematopoiesis, and marked splenomegaly. The patients with PMF have an insidious onset, a long duration of clinical course, and the deteriorated quality of life. It has been reported that the CALR gene 9 exon mutations were detected in 25–30% PMF patients, particularly as high as 80% in the JAK2/MPL-negative ones. As the second most common mutation in BCR/ABL-negative MPNs, CALR mutation has been included in the latest World Health Organization (WHO) classification criteria as one of the main diagnostic criteria for both essential thrombocythemia (ET) and PMF. Moreover, the CALR mutations indicated a favorable prognosis, which the mechanism is still under investigation. It was demonstrated that a characterized high expression of EZH2 and SUZ12 in CALR-mutated patients. Taking EZH2 as the research entry point, we initially discussed the mechanism that the CALR-positive patients with PMF exhibited a better prognosis in the current study.

Journal

Annals of Hematology – Springer Journals

Published: Mar 20, 2018

References

  • Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management
    Tefferi, A
  • Update from the latest WHO classification of MPNs: a user's manual
    Passamonti, F; Maffioli, M
  • The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
    Vardiman, JW; Thiele, J; Arber, DA; Brunning, RD; Borowitz, MJ; Porwit, A; Harris, NL; Beau, MM; Hellstrom-Lindberg, E; Tefferi, A; Bloomfield, CD
  • The dynamic international prognostic scoring system for myelofibrosis predicts outcomes after hematopoietic cell transplantation
    Scott, BL; Gooley, TA; Sorror, ML; Rezvani, AR; Linenberger, ML; Grim, J; Sandmaier, BM; Myerson, D; Chauncey, TR; Storb, R; Buxhofer-Ausch, V; Radich, JP; Appelbaum, FR; Deeg, HJ
  • Allogeneic transplantation for patients with advanced myelofibrosis: splenomegaly and high serum LDH are adverse risk factors for successful engraftment
    Gergis, U; Kuriakose, E; Shore, T; Mayer, S; Mark, T; Pearse, R; Schuster, M; Feldman, E; Roboz, G; Ritchie, E; Scandura, J; Wang, H; Zhou, XK; Silver, RT; Besien, K
  • A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
    Verstovsek, S; Mesa, RA; Gotlib, J; Levy, RS; Gupta, V; DiPersio, JF; Catalano, JV; Deininger, M; Miller, C; Silver, RT; Talpaz, M; Winton, EF; Harvey, JJ; Arcasoy, MO; Hexner, E; Lyons, RM; Paquette, R; Raza, A; Vaddi, K; Erickson-Viitanen, S; Koumenis, IL; Sun, W; Sandor, V; Kantarjian, HM
  • Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients
    Polverelli, N; Breccia, M; Benevolo, G; Martino, B; Tieghi, A; Latagliata, R; Sabattini, E; Riminucci, M; Godio, L; Catani, L; Nicolosi, M; Perricone, M; Sollazzo, D; Colafigli, G; Campana, A; Merli, F; Vitolo, U; Alimena, G; Martinelli, G; Lewis, RE; Vianelli, N; Cavo, M; Palandri, F
  • JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
    Harrison, C; Kiladjian, JJ; Al-Ali, HK; Gisslinger, H; Waltzman, R; Stalbovskaya, V; McQuitty, M; Hunter, DS; Levy, R; Knoops, L; Cervantes, F; Vannucchi, AM; Barbui, T; Barosi, G
  • Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms
    Pieri, L; Paoli, C; Arena, U; Marra, F; Mori, F; Zucchini, M; Colagrande, S; Castellani, A; Masciulli, A; Rosti, V; Stefano, V; Betti, S; Finazzi, G; Ferrari, ML; Rumi, E; Ruggeri, M; Nichele, I; Guglielmelli, P; Fjerza, R; Mannarelli, C; Fanelli, T; Merli, L; Corbizi, FG; Massa, M; Cimino, G; Rambaldi, A; Barosi, G; Cazzola, M; Barbui, T; Vannucchi, AM
  • Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study
    Campbell, PJ; Scott, LM; Buck, G; Wheatley, K; East, CL; Marsden, JT; Duffy, A; Boyd, EM; Bench, AJ; Scott, MA; Vassiliou, GS; Milligan, DW; Smith, SR; Erber, WN; Bareford, D; Wilkins, BS; Reilly, JT; Harrison, CN; Green, AR
  • SomaticCALRMutations in Myeloproliferative Neoplasms with NonmutatedJAK2
    Nangalia, J; Massie, CE; Baxter, EJ; Nice, FL; Gundem, G; Wedge, DC; Avezov, E; Li, J; Kollmann, K; Kent, DG; Aziz, A; Godfrey, AL; Hinton, J; Martincorena, I; Loo, P; Jones, AV; Guglielmelli, P; Tarpey, P; Harding, HP; Fitzpatrick, JD; Goudie, CT; Ortmann, CA; Loughran, SJ; Raine, K; Jones, DR; Butler, AP; Teague, JW; O'Meara, S; McLaren, S; Bianchi, M; Silber, Y; Dimitropoulou, D; Bloxham, D; Mudie, L; Maddison, M; Robinson, B; Keohane, C; Maclean, C; Hill, K; Orchard, K; Tauro, S; Du, MQ; Greaves, M; Bowen, D; Huntly, BJ; Harrison, CN; Cross, NC; Ron, D; Vannucchi, AM; Papaemmanuil, E; Campbell, PJ; Green, AR
  • Somatic mutations of calreticulin in myeloproliferative neoplasms
    Klampfl, T; Gisslinger, H; Harutyunyan, AS; Nivarthi, H; Rumi, E; Milosevic, JD; Them, NC; Berg, T; Gisslinger, B; Pietra, D; Chen, D; Vladimer, GI; Bagienski, K; Milanesi, C; Casetti, IC; Sant'Antonio, E; Ferretti, V; Elena, C; Schischlik, F; Cleary, C; Six, M; Schalling, M; Schonegger, A; Bock, C; Malcovati, L; Pascutto, C; Superti-Furga, G; Cazzola, M; Kralovics, R
  • Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
    Rumi, E; Pietra, D; Pascutto, C; Guglielmelli, P; Martinez-Trillos, A; Casetti, I; Colomer, D; Pieri, L; Pratcorona, M; Rotunno, G; Sant'Antonio, E; Bellini, M; Cavalloni, C; Mannarelli, C; Milanesi, C; Boveri, E; Ferretti, V; Astori, C; Rosti, V; Cervantes, F; Barosi, G; Vannucchi, AM; Cazzola, M
  • Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis
    Barbui, T; Thiele, J; Vannucchi, AM; Tefferi, A
  • CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
    Tefferi, A; Lasho, TL; Finke, CM; Knudson, RA; Ketterling, R; Hanson, CH; Maffioli, M; Caramazza, D; Passamonti, F; Pardanani, A
  • Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact
    Tefferi, A; Lasho, TL; Finke, C; Belachew, AA; Wassie, EA; Ketterling, RP; Hanson, CA; Pardanani, A
  • Improved survival of calreticulin-mutated patients compared with Janus kinase 2 in primary myelofibrosis: a meta-analysis
    Kourie, HR; Ameye, L; Paesmans, M; Bron, D
  • The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies
    Luo, B; Lee, AS
  • Calreticulin signaling in health and disease
    Wang, WA; Groenendyk, J; Michalak, M
  • The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms
    Wu, Z; Zhang, X; Xu, X; Chen, Y; Hu, T; Kang, Z; Li, S; Wang, H; Liu, W; Ma, X; Guan, M
  • Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value
    Vannucchi, AM; Rotunno, G; Bartalucci, N; Raugei, G; Carrai, V; Balliu, M; Mannarelli, C; Pacilli, A; Calabresi, L; Fjerza, R; Pieri, L; Bosi, A; Manfredini, R; Guglielmelli, P
  • Calreticulin mutations in myeloproliferative neoplasms
    Lavi, N
  • Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations
    Andrikovics, H; Krahling, T; Balassa, K; Halm, G; Bors, A; Koszarska, M; Batai, A; Dolgos, J; Csomor, J; Egyed, M; Sipos, A; Remenyi, P; Tordai, A; Masszi, T
  • Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
    Rampal, R; Al-Shahrour, F; Abdel-Wahab, O; Patel, JP; Brunel, JP; Mermel, CH; Bass, AJ; Pretz, J; Ahn, J; Hricik, T; Kilpivaara, O; Wadleigh, M; Busque, L; Gilliland, DG; Golub, TR; Ebert, BL; Levine, RL
  • The roles of EZH2 in cell lineage commitment
    Chou, RH; Yu, YL; Hung, MC
  • Role of the polycomb repressive complex 2 (PRC2) in transcriptional regulation and cancer
    Laugesen, A; Højfeldt, JW; Helin, K
  • Atg3 overexpression enhances bortezomib-induced cell death in SKM-1 cell
    Zhuang, L; Ma, Y; Wang, Q; Zhang, J; Zhu, C; Zhang, L; Xu, X
  • Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies
    Khan, SN; Jankowska, AM; Mahfouz, R; Dunbar, AJ; Sugimoto, Y; Hosono, N; Hu, Z; Cheriyath, V; Vatolin, S; Przychodzen, B; Reu, FJ; Saunthararajah, Y; O'Keefe, C; Sekeres, MA; List, AF; Moliterno, AR; McDevitt, MA; Maciejewski, JP; Makishima, H
  • Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies
    Sashida, G; Iwama, A
  • Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
    Ernst, T; Chase, AJ; Score, J; Hidalgo-Curtis, CE; Bryant, C; Jones, AV; Waghorn, K; Zoi, K; Ross, FM; Reiter, A; Hochhaus, A; Drexler, HG; Duncombe, A; Cervantes, F; Oscier, D; Boultwood, J; Grand, FH; Cross, NC
  • Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
    Score, J; Hidalgo-Curtis, C; Jones, AV; Winkelmann, N; Skinner, A; Ward, D; Zoi, K; Ernst, T; Stegelmann, F; Dohner, K; Chase, A; Cross, NC
  • Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion
    Han, L; Schubert, C; Kohler, J; Schemionek, M; Isfort, S; Brummendorf, TH; Koschmieder, S; Chatain, N
  • Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms
    Araki, M; Yang, Y; Masubuchi, N; Hironaka, Y; Takei, H; Morishita, S; Mizukami, Y; Kan, S; Shirane, S; Edahiro, Y; Sunami, Y; Ohsaka, A; Komatsu, N
  • Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum
    Michalak, M; Groenendyk, J; Szabo, E; Gold, LI; Opas, M
  • Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism
    Garbati, MR; Welgan, CA; Landefeld, SH; Newell, LF; Agarwal, A; Dunlap, JB; Chourasia, TK; Lee, H; Elferich, J; Traer, E; Rattray, R; Cascio, MJ; Press, RD; Bagby, GC; Tyner, JW; Druker, BJ; Dao, KH
  • Structural and functional relationships between the lectin and arm domains of calreticulin
    Pocanschi, CL; Kozlov, G; Brockmeier, U; Brockmeier, A; Williams, DB; Gehring, K
  • Calreticulin gene mutations in myeloproliferative neoplasms without Janus kinase 2 mutations
    Sun, C; Zhang, S; Li, J
  • Calreticulin is a receptor for nuclear export
    Holaska, JM; Black, BE; Love, DC; Hanover, JA; Leszyk, J; Paschal, BM
  • Uncovering the roles of miRNAs and their relationship with androgen receptor in prostate cancer
    Chun Jiao, S; Huan, C; Chao Yang, X; Guo Mei, R
  • Celastrol induces autophagy by targeting AR/miR-101 in prostate cancer cells
    Guo, J; Huang, X; Wang, H; Yang, H
  • MicroRNAs as regulators of signal transduction in urological tumors
    Fendler, A; Stephan, C; Yousef, GM; Jung, K
  • Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes
    Takeshita, F; Patrawala, L; Osaki, M; Takahashi, RU; Yamamoto, Y; Kosaka, N; Kawamata, M; Kelnar, K; Bader, AG; Brown, D
  • Identification of novel AR-targeted microRNAs mediating androgen signalling through critical pathways to regulate cell viability in prostate cancer
    Mo, W; Zhang, J; Li, X; Meng, D; Gao, Y; Yang, S; Wan, X; Zhou, C; Guo, F; Huang, Y; Amente, S; Avvedimento, EV; Xie, Y; Li, Y
  • Prolonged Ezh2 depletion in glioblastoma causes a robust switch in cell fate resulting in tumor progression
    Vries, NA; Hulsman, D; Akhtar, W; Jong, J; Miles, DC; Blom, M; Tellingen, O; Jonkers, J; Lohuizen, M